Format

Send to

Choose Destination
Int J Infect Dis. 2017 Mar;56:263-267. doi: 10.1016/j.ijid.2016.10.018. Epub 2016 Nov 2.

Novel approaches to tuberculosis vaccine development.

Author information

1
Max Planck Institute for Infection Biology, Department of Immunology, Charitéplatz 1, 10117 Berlin, Germany. Electronic address: Kaufmann@mpiib-berlin.mpg.de.
2
Max Planck Institute for Infection Biology, Department of Immunology, Charitéplatz 1, 10117 Berlin, Germany.
3
Infectious Disease and International Health, Geisel School of Medicine, Hanover, New Hampshire, USA.

Abstract

Tuberculosis (TB) remains the deadliest infectious disease. The widely used bacille Calmette-Guérin (BCG) vaccine offers only limited protection against TB. New vaccine candidates for TB include subunit vaccines and inactivated whole-cell vaccines, as well as live mycobacterial vaccines. Current developments in TB vaccines are summarized in this review.

KEYWORDS:

Post-exposure vaccine; Pre-exposure vaccine; Preventive vaccine; Subunit vaccine; Therapeutic vaccine; Whole-cell vaccine

PMID:
27816661
DOI:
10.1016/j.ijid.2016.10.018
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center